Insight Molecular Diagnostics
IMDX
35 hedge funds and large institutions have $125M invested in Insight Molecular Diagnostics in 2025 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 1 closing their positions.
800% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 1
800% more call options, than puts
Call options by funds: $9K | Put options by funds: $1K
131% more capital invested
Capital invested by funds: $54.1M → $125M (+$70.8M)
30% more funds holding
Funds holding: 27 → 35 (+8)
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
1.2% more ownership
Funds ownership: 56.89% → 58.09% (+1.2%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$436K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$409K |
| 3 |
BlackRock
New York
|
+$245K |
| 4 |
Jane Street
New York
|
+$240K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$225K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$148K |
| 2 |
FIA
FNY Investment Advisers
New York
|
-$70.5K |
| 3 |
Millennium Management
New York
|
-$67.2K |
| 4 |
Renaissance Technologies
New York
|
-$57.6K |
| 5 |
AIC
AWM Investment Company
New York
|
-$46.8K |
IMDX Hedge Fund Activity: Q4 2025 in Review
35 of the 8,225 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q4 2025, worth a combined $125M — up 131% from $54.1M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new IMDX positions and 1 closed out — a net gain of 8 holders — while 8 added to existing stakes and 7 trimmed.
The largest buyer was 683 Capital Management, opening a new position worth an estimated $436K. The largest seller was Morgan Stanley, cutting an estimated $148K.
- 35 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q4 2025, up from 27 in Q3 2025.
- Funds reported $125M of Insight Molecular Diagnostics stock for Q4 2025, up 131% quarter-over-quarter.
- 9 funds opened new Insight Molecular Diagnostics positions in Q4 2025 and 1 closed out, a net change of +8 holders.
- The largest Insight Molecular Diagnostics buyer in Q4 2025 was 683 Capital Management, an estimated $436K added.
- The largest Insight Molecular Diagnostics seller in Q4 2025 was Morgan Stanley, an estimated $148K sold.
Based on aggregated 13F filings for Q4 2025.